Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

56.20 -0.57 (-1.00%)
Streaming Delayed Price Updated: 12:51 PM EST, Feb 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
35 36 Next >
News headline image
TGT Stock Alert: Have Target’s Sales Numbers Peaked? ↗
Target (TGT) stock is in hot water on Friday after Citi analyst Paul Lejuez warned investors to stay away from the retailer. 
Via InvestorPlace
News headline image
Why Is CRISPR Therapeutics (CRSP) Stock Moving Today? ↗
CRISPR Therapeutics (CRSP) stock is on the move Friday after the company revealed data from its CLIMB-111 and CLIMB-121 clinical trials. 
Via InvestorPlace
News headline image
Crispr Stock Slips; The FDA Could Approve The First CRISPR-Based Gene-Editing Drug In Just Six Months ↗
The agency said it will make an approval decision on Crispr's exa-cel in December. 
Via Investor's Business Daily
News headline image
Wall Street Loves These 3 Growth Stocks -- Should You? ↗
Analysts think all three of these stocks could soar. 
Via The Motley Fool
News headline image
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Can This Gene-Editing Stock Deliver 10X Returns? ↗
Buying shares of Intellia Therapeutics might be a smart move. 
Via The Motley Fool
News headline image
CRISPR Therapeutics: A Galaxy's Worth of Deep Value ↗
Wall Street is at max pessimism with this biotech, which might be a big mistake. 
Via The Motley Fool
News headline image
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? ↗
Today, CRISPR has reached an important turning point. 
Via The Motley Fool
News headline image
Cathie Wood Is Buying the SEC Lawsuit Dip in Coinbase (COIN) Stock ↗
Coinbase and the crypto industry at large is at war with regulators. But Cathie Wood is still buying shares of COIN stock. 
Via InvestorPlace
News headline image
Why Are Gene Editing Stocks EDIT, NVTA, CRSP Up Today? ↗
Gene editing stocks are up today on news that Editas Medicine will present clinical data on June 12. Here's what this means for the sector. 
Via InvestorPlace
News headline image
3 Disruptors I Love Right Now ↗
These stocks could deliver huge returns as the companies transform the economy. 
Via The Motley Fool
News headline image
CRISPR Therapeutics Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
News headline image
Analyst Expectations for CRISPR Therapeutics's Future ↗
 
Via Benzinga
News headline image
Is CRISPR Therapeutics Stock a Buy Now? ↗
The clinical-stage biotech company has been on the rise. 
Via The Motley Fool
News headline image
3 Top Healthcare Stocks to Buy for June ↗
These stocks have what it takes to deliver long-term growth. 
Via The Motley Fool
News headline image
Prediction: These 2 Stocks Could Double In the Next Year ↗
It would be a continuation of solid recent performances. 
Via The Motley Fool
News headline image
3 No-Brainer Stocks to Buy for Under $100 Right Now ↗
These stocks might not remain under $100 for too much longer. 
Via The Motley Fool
News headline image
2 Supercharged Stocks to Buy With $100 ↗
These stocks are climbing in the double digits. 
Via The Motley Fool
News headline image
2 Top Trends to Invest $5,000 in Right Now ↗
Renewable energy and gene-editing medical therapies are poised to grow exponentially. 
Via The Motley Fool
News headline image
Better Growth Stock: CRISPR Therapeutics vs. Teladoc Health ↗
Both stocks are recovering after big losses last year. 
Via The Motley Fool
News headline image
A Good Week For The Market But A Pause In The Biotech Rally ↗
Healthcare stocks have been lagging in 2023 with the XLV down 1.97% MTD and 3.34% YTD with CVS and UNH contributing to the weakness. 
Via Talk Markets
News headline image
Cathie Wood Just Sold CRISPR Therapeutics Stock. Here's Why You Should Consider Buying It ↗
Her investing thesis for holding it is probably the same as ever. 
Via The Motley Fool
News headline image
Cathie Wood Is Buying This Biotech Stock Like Wildfire, But Should You? ↗
It's facing a few issues that are practically guaranteed to affect shareholder returns. 
Via The Motley Fool
News headline image
3 Biotech Stocks That Are Revolutionizing Healthcare in 2023 ↗
Here are three of the best biotech stocks to buy; each is on the verge of significant breakthroughs that may send the price higher. 
Via InvestorPlace
News headline image
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets. 
Via MarketBeat
News headline image
2 Stocks You'll Be Glad You Bought at These Prices ↗
Bear markets create opportunities to buy high-growth stocks at discounted valuations. 
Via The Motley Fool
News headline image
2 Soaring Growth Stocks That Could Rocket Even Higher ↗
One of these stocks is up 57% this year, and the other one has more than tripled already. 
Via The Motley Fool
News headline image
Why These 3 Nasdaq Stocks Were Glowing Green This Week ↗
These three biopharmaceutical stocks rocketed higher this week. 
Via The Motley Fool
News headline image
Devon Energy, CRISPR Therapeutics, And Bullish On Berkshire Succession: CNBC's 'Final Trades' ↗
On CNBC’s "Halftime Report Final Trades," Joseph Terranova of Virtus Investment Partners said CRISPR Therapeutics AG (NASDAQ: CRSP) reported strong 
Via Benzinga
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.